Glutathione

Glutathione is a tripeptide composed of three amino acids: glutamate, cysteine, and glycine, joined by an unusual peptide bond between the gamma-carboxyl group of glutamate and the amino group of cysteine. Its chemical designation is gamma-L-glutamyl-L-cysteinylglycine (GSH). Glutathione is the most abundant intracellular antioxidant in the human body, present in virtually every cell, with particularly high concentrations in the liver, which relies on it for detoxification. The body produces glutathione endogenously, but production declines with age, poor nutrition, chronic illness, oxidative stress, and certain medications. This decline is associated with accelerated cellular aging and reduced resilience to metabolic insults.

The core antioxidant mechanism of glutathione operates through its sulfur-containing thiol (-SH) group on the cysteine residue. This thiol group donates electrons to neutralize reactive oxygen species (ROS), free radicals, and peroxides. The reaction is catalyzed primarily by glutathione peroxidases (GPxs), which convert harmful peroxides to water while oxidizing GSH to its disulfide form (GSSG). The cell then regenerates GSH from GSSG via glutathione reductase using NADPH as the electron donor, creating a continuous antioxidant recycling cycle. Beyond direct radical scavenging, glutathione participates in the detoxification of xenobiotics through glutathione S-transferase enzymes, conjugating toxic compounds for excretion. It also maintains the reduced state of other antioxidants including vitamins C and E, amplifying their effectiveness.

Clinical research on injectable glutathione covers several domains. In Parkinson's disease, small pilot studies have suggested that intravenous glutathione may temporarily improve motor symptoms, though larger controlled trials have not confirmed consistent benefit. In non-alcoholic fatty liver disease (NAFLD), a Japanese study found that intravenous GSH at 1,200 mg/day for 4 months reduced liver enzyme levels and markers of oxidative stress compared to placebo. Skin-lightening studies have examined glutathione's ability to shift melanin synthesis from darker eumelanin to lighter phaeomelanin; a systematic review published in PMC found evidence of modest efficacy at 500-2,000 mg IV weekly but noted significant study quality limitations. Regarding pharmacokinetics, IV glutathione achieves immediate systemic bioavailability, but plasma half-life is extremely short (on the order of minutes), with rapid uptake by tissues and renal clearance limiting circulating concentrations.

It is important to note that oral glutathione has very poor bioavailability due to intestinal degradation. Liposomal oral formulations and precursor supplementation (N-acetylcysteine, alpha-lipoic acid) offer alternative strategies for raising intracellular GSH. Injectable glutathione bypasses this absorption problem but introduces its own risks including anaphylaxis risk with intravenous administration and concerns about non-physiological plasma concentrations causing reductive stress that impairs mitochondrial and immune function if doses are excessive.